Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
- Registration Number
- NCT03164291
- Brief Summary
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
- Detailed Description
Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 170
Inclusion Criteria
- Adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria
Exclusion Criteria
- Children less than 18 years of age
- Pregnancy
- Low platelet count, except with very serious disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Rifabutin Rifabutin Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
- Primary Outcome Measures
Name Time Method Clinical and microbiological outcomes (e.g. clinical symptoms, laboratory cultures) 6 mos neg cultures X3( sputum conversion)
- Secondary Outcome Measures
Name Time Method Microbiological Cultures 1year neg cultures for 1 yr on treatment
Trial Locations
- Locations (1)
The University of Texas Health Science Center at Tyler
🇺🇸Tyler, Texas, United States